Sinotherapeutics

Sinotherapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinotherapeutics (688247.SS) as of Oct 15, 2026 is 61.52 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 140.89 M CNY — a change of -56.33% (lower).

EBITDA

61.52 MCNY

YoY

-56.33%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinotherapeutics is 2025 61.52 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinotherapeutics was 2024 140.89 M CNY. It decreases by -56.33% lower compared to the previous year.

The Sinotherapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
1.49 M CNY
Jan 1, 2020
149.59 M CNY
Jan 1, 2021
139.51 M CNY
Jan 1, 2022
85.76 M CNY
Jan 1, 2023
66.62 M CNY
Jan 1, 2024
140.89 M CNY
Jan 1, 2025
61.52 M CNY
The Sinotherapeutics EBITDA history
YEAREBITDAYoY
61.52 MCNY-56.33%
140.89 MCNY+111.48%
66.62 MCNY-22.32%
85.76 MCNY-38.53%
139.51 MCNY-6.74%
149.59 MCNY+9,922.16%
1.49 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sinotherapeutics Stock analysis

What does Sinotherapeutics do? Sinotherapeutics Inc is a pharmaceutical company based in Shanghai, China, operating within the Health Care sector. The company focuses on the research and development, production, and sales of high-end generic drugs, alongside offering Contract Research Organization (CRO) services. Sinotherapeutics went public with an IPO on August 25, 2022, and currently employs 248 full-time staff. Its primary business activities include the development, manufacturing, and distribution of generic pharmaceutical products, as well as providing CRO services to support drug development processes. The company serves both domestic and international markets, though specific details about its market presence or key products are not provided. Sinotherapeutics is listed on the Shanghai Stock Exchange under the ticker 688247.SS and holds the ISIN CNE100005PL9. The company's official website is https://www.sinotherapeutics.com/. It operates as a domestic entity with a focus on pharmaceutical innovation and service delivery within the healthcare industry. No additional details regarding acquisitions, founding year, specific product names, or financial figures are available from the provided information. Sinotherapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinotherapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinotherapeutics is 61.52 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sinotherapeutics changed from 140.89 M CNY to 61.52 M CNY, representing a -56.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sinotherapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sinotherapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Sinotherapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Sinotherapeutics